

Nicolas Verheyen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1155835/publications.pdf>

Version: 2024-02-01

58
papers

2,035
citations

304743

22
h-index

243625

44
g-index

59
all docs

59
docs citations

59
times ranked

3878
citing authors

#	ARTICLE	IF	CITATIONS
1	Expression Profiles of miR-22-5p and miR-142-3p Indicate Hashimoto's Disease and Are related to Thyroid Antibodies. <i>Genes</i> , 2022, 13, 171.	2.4	9
2	DXA-Derived Indices in the Characterisation of Sarcopenia. <i>Nutrients</i> , 2022, 14, 186.	4.1	8
3	Prevalence and prognostic factors for aortic dilatation in giant cell arteritis – a longitudinal study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 911-918.	3.4	16
4	Circulating uromodulin inhibits vascular calcification by interfering with pro-inflammatory cytokine signalling. <i>Cardiovascular Research</i> , 2021, 117, 930-941.	3.8	38
5	Associations of Serum Cortisol with Cardiovascular Risk and Mortality in Patients Referred to Coronary Angiography. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab017.	0.2	6
6	Advanced isolated light chain amyloid cardiomyopathy with negative immunofixation and normal free light chain ratio. <i>ESC Heart Failure</i> , 2021, 8, 3397-3402.	3.1	3
7	Worsening Heart Failure After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, e253-e255.	2.9	1
8	Myocardial Deformation Analysis in MYBPC3 and MYH7 Related Sarcomeric Hypertrophic Cardiomyopathy – The Graz Hypertrophic Cardiomyopathy Registry. <i>Genes</i> , 2021, 12, 1469.	2.4	5
9	Impact of EMPagliflozin on cardiac function and biomarkers of heart failure in patients with acute Myocardial infarction – The EMMY trial. <i>American Heart Journal</i> , 2020, 221, 39-47.	2.7	43
10	Indications and Outcome in Patients Undergoing Left Atrial Appendage Closure – The Austrian LAAC Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 3274.	2.4	6
11	Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 742-761.	1.9	31
12	Associations of Thyroid Hormones and Resting Heart Rate in Patients Referred to Coronary Angiography. <i>Hormone and Metabolic Research</i> , 2020, 52, 850-855.	1.5	3
13	Effect of Galectin 3 on Aldosterone-Associated Risk of Cardiovascular Mortality in Patients Undergoing Coronary Angiography. <i>American Journal of Cardiology</i> , 2020, 127, 9-15.	1.6	2
14	Stork leg sign in acute pericarditis. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 683-684.	0.4	0
15	Myocardial GLP-1 Receptor Activation in the Presence of Glucose: Strong Partners. <i>International Journal of Peptide Research and Therapeutics</i> , 2019, 25, 605-612.	1.9	0
16	Alternate Day Fasting Improves Physiological and Molecular Markers of Aging in Healthy, Non-obese Humans. <i>Cell Metabolism</i> , 2019, 30, 462-476.e6.	16.2	256
17	Diagnostic Accuracy of the Aldosterone-to-Active Renin Ratio for Detecting Primary Aldosteronism. <i>Journal of the Endocrine Society</i> , 2019, 3, 1748-1758.	0.2	6
18	The endogenous cardioprotective steroid Marinobufagenin and decline in estimated glomerular filtration rate at follow-up in patients with arterial hypertension. <i>PLoS ONE</i> , 2019, 14, e0212973.	2.5	5

#	ARTICLE	IF	CITATIONS
19	Exercise training in patients with a left ventricular assist device (ExLVAD): rationale and design of a multicentre, prospective, assessor-blinded, randomized, controlled trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1152-1159.	7.1	19
20	Diastolic stress test echocardiography in patients with suspected heart failure with preserved ejection fraction: a pilot study. <i>ESC Heart Failure</i> , 2019, 6, 146-153.	3.1	32
21	Effects of vitamin D supplementation on FGF23: a randomized-controlled trial. <i>European Journal of Nutrition</i> , 2019, 58, 697-703.	3.9	19
22	Unfolding Cardiac Amyloidosis –From Pathophysiology to Cure. <i>Current Medicinal Chemistry</i> , 2019, 26, 2865-2878.	2.4	13
23	Thermic sealing in femoral catheterization: First experience with the Secure Device. <i>Cardiology Journal</i> , 2019, 26, 233-240.	1.2	1
24	Are soluble ST2 levels influenced by vitamin D and/or the seasons?. <i>Endocrine Connections</i> , 2019, 8, 691-700.	1.9	1
25	Zinc Inhibits Phosphate-Induced Vascular Calcification through TNFAIP3-Mediated Suppression of NF- κ B. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1636-1648.	6.1	109
26	Lancisi sign in a 69-year-old man with severe tricuspid regurgitation. <i>Cmaj</i> , 2018, 190, E17-E17.	2.0	1
27	Mineralocorticoid Receptor Blockers and Aldosterone to Renin Ratio: A Randomized Controlled Trial and Observational Data. <i>Hormone and Metabolic Research</i> , 2018, 50, 375-382.	1.5	10
28	Vitamin D supplementation and lipoprotein metabolism: A randomized controlled trial. <i>Journal of Clinical Lipidology</i> , 2018, 12, 588-596.e4.	1.5	36
29	Homoarginine/ADMA ratio and homoarginine/SDMA ratio as independent predictors of cardiovascular mortality and cardiovascular events in lower extremity arterial disease. <i>Scientific Reports</i> , 2018, 8, 14197.	3.3	24
30	The Bone-Cardiovascular Axis: Mechanisms and Clinical Relevance. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-2.	1.5	5
31	Age-dependent effects of homocysteine and dimethylarginines on cardiovascular mortality in claudicant patients with lower extremity arterial disease. <i>Heart and Vessels</i> , 2018, 33, 1453-1462.	1.2	9
32	Rationale and Plan for Vitamin D Food Fortification: A Review and Guidance Paper. <i>Frontiers in Endocrinology</i> , 2018, 9, 373.	3.5	249
33	Intermittent Fasting (Alternate Day Fasting) in Healthy, Non-obese Adults: Protocol for a Cohort Trial with an Embedded Randomized Controlled Pilot Trial. <i>Advances in Therapy</i> , 2018, 35, 1265-1283.	2.9	15
34	Vitamin D: Current Guidelines and Future Outlook. <i>Anticancer Research</i> , 2018, 38, 1145-1151.	1.1	37
35	Low-grade inflammation and tryptophan-kynurenine pathway activation are associated with adverse cardiac remodeling in primary hyperparathyroidism: the EPATH trial. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 1034-1042.	2.3	15
36	Vitamin-D concentrations, cardiovascular risk and events - a review of epidemiological evidence. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 259-272.	5.7	59

#	ARTICLE	IF	CITATIONS
37	Plasma parathyroid hormone and cardiovascular disease in treatment-naïve patients with primary hyperparathyroidism: The EPATH trial. <i>Journal of Clinical Hypertension</i> , 2017, 19, 1173-1180.	2.0	14
38	Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism – The randomized, placebo-controlled EPATH trial. <i>Bone</i> , 2017, 105, 212-217.	2.9	8
39	Long-Term Renal and Cardiac Outcomes after Stenting in Patients with Resistant Hypertension and Atherosclerotic Renal Artery Stenosis. <i>Kidney and Blood Pressure Research</i> , 2017, 42, 774-783.	2.0	9
40	Effects of Vitamin D Supplementation on Bone Turnover Markers: A Randomized Controlled Trial. <i>Nutrients</i> , 2017, 9, 432.	4.1	39
41	The Synergistic Interplay between Vitamins D and K for Bone and Cardiovascular Health: A Narrative Review. <i>International Journal of Endocrinology</i> , 2017, 2017, 1-12.	1.5	55
42	Effects of Vitamin D Supplementation on IGF-1 and Calcitriol: A Randomized-Controlled Trial. <i>Nutrients</i> , 2017, 9, 623.	4.1	33
43	Relationship between bone turnover and left ventricular function in primary hyperparathyroidism: The EPATH trial. <i>PLoS ONE</i> , 2017, 12, e0173799.	2.5	10
44	Beneficial Effects of UV-Radiation: Vitamin D and beyond. <i>International Journal of Environmental Research and Public Health</i> , 2016, 13, 1028.	2.6	16
45	Vitamin D Supplementation and Hemoglobin Levels in Hypertensive Patients: A Randomized Controlled Trial. <i>International Journal of Endocrinology</i> , 2016, 2016, 1-7.	1.5	19
46	Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism. <i>Journal of Hypertension</i> , 2016, 34, 1347-1356.	0.5	22
47	Strain Analysis by Tissue Doppler Imaging: Comparison of Conventional Manual Measurement with a Semiautomated Approach. <i>Echocardiography</i> , 2016, 33, 372-378.	0.9	3
48	Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism. <i>Journal of Hypertension</i> , 2016, 34, 1778-1786.	0.5	17
49	Vitamin D and cardiovascular disease prevention. <i>Nature Reviews Cardiology</i> , 2016, 13, 404-417.	13.7	250
50	Effects of Vitamin D Supplementation on Plasma Aldosterone and Renin – A Randomized Placebo-Controlled Trial. <i>Journal of Clinical Hypertension</i> , 2016, 18, 608-613.	2.0	34
51	Vitamin D and Mortality. <i>Anticancer Research</i> , 2016, 36, 1379-87.	1.1	28
52	Plasma Aldosterone and Left Ventricular Diastolic Function in Treatment-Naïve Patients With Hypertension. <i>Hypertension</i> , 2015, 65, 1231-1237.	2.7	31
53	Effects of Vitamin D on Blood Pressure and Cardiovascular Risk Factors. <i>Hypertension</i> , 2015, 65, 1195-1201.	2.7	152
54	Homoarginine in Patients With Primary Hyperparathyroidism. <i>American Journal of the Medical Sciences</i> , 2015, 349, 306-311.	1.1	8

#	ARTICLE	IF	CITATIONS
55	Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 20-31.	3.4	133
56	Cinacalcet hydrochloride for the treatment of hyperparathyroidism. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 793-806.	1.8	31
57	The importance of assays in vitamin D status classification: a comparison of four automated 25-hydroxyvitamin D immunoassays. <i>Laboratoriums Medizin</i> , 2013, 37, 261-268.	0.6	7
58	Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial. <i>BMC Endocrine Disorders</i> , 2012, 12, 19.	2.2	24